Thomas G. Gross

8.1k total citations · 1 hit paper
127 papers, 4.3k citations indexed

About

Thomas G. Gross is a scholar working on Pathology and Forensic Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Thomas G. Gross has authored 127 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pathology and Forensic Medicine, 54 papers in Oncology and 33 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Thomas G. Gross's work include Lymphoma Diagnosis and Treatment (54 papers), Viral-associated cancers and disorders (42 papers) and Acute Lymphoblastic Leukemia research (32 papers). Thomas G. Gross is often cited by papers focused on Lymphoma Diagnosis and Treatment (54 papers), Viral-associated cancers and disorders (42 papers) and Acute Lymphoblastic Leukemia research (32 papers). Thomas G. Gross collaborates with scholars based in United States, Canada and Australia. Thomas G. Gross's co-authors include E. Steve Woodle, Joseph F. Buell, Amanda Termuhlen, M. Roy First, Rita R. Alloway, Mitchell S. Cairo, Sherrie L. Perkins, Motohiko Okano, Lynette M. Smith and Thomas A. Seemayer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Thomas G. Gross

126 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge

2015 280 citations Catherine Patte, Thomas G. Gross et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas G. Gross United States	37	2.1k	1.4k	1.0k	974	832	127	4.3k
Mehdi Hamadani United States	37	3.4k 1.6×	1.7k 1.2×	1.1k 1.1×	2.5k 2.6×	702 0.8×	411	6.2k
Olivier Tournilhac France	36	1.5k 0.7×	1.9k 1.3×	1.6k 1.6×	1.5k 1.6×	790 0.9×	180	4.8k
Philip A. Rowlings United States	25	1.6k 0.8×	799 0.6×	894 0.9×	2.8k 2.8×	902 1.1×	36	4.4k
Laura C. Bowman United States	42	2.3k 1.1×	628 0.4×	860 0.8×	788 0.8×	531 0.6×	107	5.8k
Howard J. Weinstein United States	43	1.2k 0.6×	1.4k 1.0×	508 0.5×	2.2k 2.3×	1.6k 1.9×	122	5.4k
Stein Kvaløy Norway	31	1.5k 0.7×	1.7k 1.2×	370 0.4×	342 0.4×	384 0.5×	94	3.2k
Keizo Horibe Japan	45	1.6k 0.8×	926 0.6×	700 0.7×	3.1k 3.2×	2.7k 3.2×	282	6.7k
Silvia Montoto United Kingdom	41	2.8k 1.4×	3.1k 2.1×	785 0.8×	1.4k 1.5×	337 0.4×	165	5.2k
Andishe Attarbaschi Austria	33	942 0.5×	980 0.7×	327 0.3×	1.1k 1.2×	1.6k 1.9×	155	3.4k
A. H. Goldstone United Kingdom	33	1.6k 0.8×	1.6k 1.1×	654 0.6×	1.4k 1.4×	479 0.6×	101	3.9k

Countries citing papers authored by Thomas G. Gross

Since Specialization

Citations

This map shows the geographic impact of Thomas G. Gross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas G. Gross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas G. Gross more than expected).

Fields of papers citing papers by Thomas G. Gross

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas G. Gross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas G. Gross. The network helps show where Thomas G. Gross may publish in the future.

Co-authorship network of co-authors of Thomas G. Gross

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas G. Gross. A scholar is included among the top collaborators of Thomas G. Gross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas G. Gross. Thomas G. Gross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shaw, Timothy I., Stanley Pounds, Xueyuan Cao, et al.. (2024). Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma. Leukemia. 39(1). 199–210. 1 indexed citations

Gross, Thomas G. & Jeremy D. Rubinstein. (2023). Post‐transplant lymphoproliferative disease in children, adolescents, and young adults. Hematological Oncology. 41(S1). 48–56. 6 indexed citations

Rubinstein, Jeremy D., et al.. (2023). Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults. Best Practice & Research Clinical Haematology. 36(1). 101446–101446. 17 indexed citations

Lowe, Eric, Anne F. Reilly, Megan S. Lim, et al.. (2022). Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1. Journal of Clinical Oncology. 41(11). 2043–2053. 25 indexed citations

Lowe, Eric, Anne F. Reilly, Megan S. Lim, et al.. (2021). Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 137(26). 3595–3603. 46 indexed citations

Hayashi, Robert J., Stuart S. Winter, Kimberly P. Dunsmore, et al.. (2020). Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434. Journal of Clinical Oncology. 38(26). 3062–3070. 38 indexed citations

Chisholm, Karen M., Jeffrey S. Mohlman, Michael Liew, et al.. (2019). IRF4 translocation status in pediatric follicular and diffuse large B‐cell lymphoma patients enrolled in Children's Oncology Group trials. Pediatric Blood & Cancer. 66(8). e27770–e27770. 20 indexed citations

Frazer, J. Kimble, Kevin J. Li, Paul J. Galardy, et al.. (2018). Excellent outcomes in children and adolescents with CNS⁺ Burkitt lymphoma or other mature B‐NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. British Journal of Haematology. 185(2). 374–377. 14 indexed citations

Smith, Lynette M., James R. Anderson, Minnie Abromowitch, et al.. (2012). The immunophenotype of T ‐lymphoblastic lymphoma in children and adolescents: a C hildren's O ncology G roup report. British Journal of Haematology. 159(4). 454–461. 69 indexed citations

10.

Gross, Thomas G., Manuela Orjuela, S L Perkins, et al.. (2012). Low-Dose Chemotherapy and Rituximab for Posttransplant Lymphoproliferative Disease (PTLD): A Children’s Oncology Group Report. American Journal of Transplantation. 12(11). 3069–3075. 110 indexed citations

11.

Soni, Sandeep, Micah Skeens, Amanda Termuhlen, et al.. (2012). Levetiracetam for busulfan‐induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatric Blood & Cancer. 59(4). 762–764. 27 indexed citations

12.

Liu, Aiguo, Li Lin, Chang‐Ching Wei, et al.. (2011). Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Investigational New Drugs. 30(3). 916–926. 49 indexed citations

13.

Klopfenstein, Kathryn J., et al.. (2009). Prevalence of abnormal bone density of pediatric patients prior to blood or marrow transplant. Pediatric Blood & Cancer. 53(4). 675–677. 9 indexed citations

14.

Smith, Angela R., Thomas G. Gross, & K. Scott Baker. (2009). Transplant Outcomes for Primary Immunodeficiency Disease. Seminars in Hematology. 47(1). 79–85. 11 indexed citations

15.

Gross, Thomas G., Gregory A. Hale, Wensheng He, et al.. (2009). Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents. Biology of Blood and Marrow Transplantation. 16(2). 223–230. 96 indexed citations

16.

Lowe, Eric, Richard Sposto, Sherrie L. Perkins, et al.. (2008). Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941. Pediatric Blood & Cancer. 52(3). 335–339. 80 indexed citations

17.

Gross, Thomas G. & Amanda Termuhlen. (2008). Pediatric non-Hodgkin lymphoma. Current Hematologic Malignancy Reports. 3(3). 167–173. 10 indexed citations

18.

Termuhlen, Amanda, et al.. (2006). Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate. Pediatric Transplantation. 10(7). 830–834. 5 indexed citations

19.

Boyer, Michael W., Thomas G. Gross, Brett Loechelt, et al.. (2003). Low Risk of Graft-Versus-Host Disease With Transplantation of CD34 Selected Peripheral Blood Progenitor Cells From Alternative Donors for Fanconi Anemia. Journal of Pediatric Hematology/Oncology. 25(11). 890–895. 20 indexed citations

20.

Seemayer, Thomas A., et al.. (1997). Cytodifferentiation of a Wilms' tumor pulmonary metastasis. Cancer. 79(8). 1629–1634. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact